Academic literature on the topic 'FIFO bi-synchrone [First In'

In order to make a convenient interface to the complexity of the timing of high-speed, high-capacity storage medium applications, a new design has been proposed for the interface device of storage media with FIFO feature based on DDRII SDRAM by this thesis. At first, the principles and implementation of DDRII SDRAM controller are introduced. Then the memory interface module has been designed based on the time-sharing technique of DDRII SDRAM. Finally, the principles of the interface controller module have been deeply analyzed and implemented by functional simulation through the Quartus II software and FPGA hardware verification. Through stimulation and verification, the high-speed memory interface controller module based on DDRII SDRAM implemented the bi-directional data transfer and interaction between DDRII memory and FPGA, which has a certain value of practical application.

El trabajo propone determinar un conjunto de indicadores acerca del desempeño de las empresas productivas del Cantón La Troncal, provincia del Cañar, Ecuador, para usar la “Inteligencia de Negocios” (Business Intelligence BI) como una mejor práctica que apoye la gestión organizacional y la consecución de los objetivos estratégicos. Para ello primero se levantó información en empresas locales, en base a una muestra específica, con instrumentos del tipo cuestionario y entrevista. Luego, a partir de la información obtenida se diseñó un cuadro de mando integral (Balanced Scorecard) con los indicadores claves de desempeño más significativos para las empresas de la muestra, de modo que se puedan implementar con los servicios multidimensionales que ofrecen las herramientas de Inteligencia de Negocios. Finalmente, los informes se representaron en tableros de control, con un rango de granularidad fino, que permitan a los directivos tomar decisiones claras, reduciendo el grado de incertidumbre. ABSTRACTThe paper aims to determine a set of indicators about the performance of productive enterprises in Canton La Troncal, province of Cañar, Ecuador, to use “Business Intelligence” (Business Intelligence BI) as the best practice that supports organizational management and achievement of the strategic objectives. For this purpose, information was first collected through a survey that was carried out in local companies, based on a specific sample, with questionnaires and interviews. Then, based on the information obtained, a Balanced Scorecard was designed with the most significant key performance indicators for the companies in the sample, so that they can be implemented with the multidimensional services offered by business intelligence tools. Finally, the reports were presented in control panels, with a fine granularity range, which allow managers to make clear decisions, reducing the degree of uncertainty.

Background Richter syndrome (RS) refers as to the onset of aggressive lymphoma, mostly diffuse large B cell lymphoma (DLBCL), in patients (pts) with chronic lymphocytic leukemia (CLL). The outcome of RS pts is usually very poor with both low response rates to chemoimmunotherapy and short survival, except for the minority of them whose tumor cells are clonally unrelated to the underlying CLL. While BCR and BCL2 inhibitors have transformed the management of CLL pts, these drugs do not prevent the onset of RS. Modulating anti-tumor immunity has recently been suggested as a promising approach in RS (Ding, 2017). Blinatumomab is a bi-specific T-cell engaging antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell activation and subsequent lysis of tumor cells. It has been approved for the treatment of pts with relapsed or refractory B-ALL and has also been evaluated in the setting of persisting minimal residual disease. More recently, blinatumomab (stepwise dosing 9-28-112 μg/d) has been evaluated in pts with relapsed or refractory DLBCL and demonstrated promising results (ORR 43%) with acceptable safety (Viardot, 2016). We hypothesized that blinatumomab would improve response in RS pts failing to achieve CR after initial debulking with R-CHOP. Methods We report here the first results of a currently ongoing phase 2 multicenter study investigating the efficacy and safety of blinatumomab after R-CHOP debulking therapy for pts with untreated RS of DLBCL histology (NCT03931642). The pts achieving complete remission (CR) after 2 cycles of R-CHOP21 discontinued study while those with persisting (PR, SD) or progressive disease (PD) were eligible to receive an 8-week course of blinatumomab induction. An additional 4-week consolidation cycle was optional and might be proposed according to the treating-physician decision, especially in pts who were ineligible for stem-cell transplantation. Blinatumomab was administered at a stepwise dose of 9 μg/d in the first week, 28 μg/d in the second week, and 112 μg/d thereafter. The primary endpoint was CR rate according to the revised Lugano criteria after the 8-week induction course of blinatumomab. Interim analysis (Simon two-stage design) was planned after completion of blinatumomab induction in 10 pts. Results A total of 15 pts out of 35 has already been enrolled in the trial to date. Median age was 67 years (range, 38-80) andsex ratioM/F was 12/3. CLL features at baseline were as follows: 9/15 (60%) pts hadTP53alterations and 10/13 (77%) unmutated IGHV status. Median number of prior therapeutic lines for CLL was 2 (range, 0-4): 10 (67%) pts previously received chemo-immunotherapy, 10 (67%) pts were exposed to BCR inhibitors and 3 (20%) to venetoclax. As of the data cut-off of July 1st, 2020, the blinatumomab induction course has been completed for 5 pts while it is still on-going in 3 others. Three pts are still on R-CHOP debulking. Four pts discontinued study before receiving blinatumomab for the following reasons: 2 pts achieved CR after R-CHOP, 1 patient died because of febrile neutropenia after R-CHOP and 1 patient discontinued study before starting R-CHOP (no RS criteria after pathology review). Regarding toxicity during blinatumomab, data are available for the 5 pts having completed the blinatumomab induction to date. Four pts had at least one grade 1 adverse event (AE), 2 had grade ≥3 AE. The most common AE, regardless of relationship to blinatumomab, were grade 1 fever (2 pts) and grade 2 leukopenia (2 pts). Other grade >1 AE were observed in 1 pt only (grade 3 anxiety, grade 2 anemia, grade 2 neutropenia, grade 3 lymphopenia). In terms of neurologic event, 1 pt had grade 1 AE (paresthesia, myoclonus and muscle contraction) and another one presented grade 4 confusion while on first 9 μg/d dose leading to permanent discontinuation of blinatumomab. In terms of efficacy, after R-CHOP debulking therapy (n=10 evaluable pts), 2 pts achieved CR (and did not pursuit on study), 5 pts were in PR and 3 pts were progressive. At evaluation after the blinatumomab induction (n=5 evaluable pts), 2 pts achieved CR, 1 patient PR and 2 pts were progressive. Conclusions Our preliminary data suggest that blinatumomab shows encouraging anti-tumor activity and acceptable toxicity in pts with RS. Further analyses are warranted to validate these conclusions. Updated efficacy/safety in the remaining pts enrolled in the trial will be presented at the meeting. Disclosures Guieze: astrazanecka:Honoraria, Other: advisory board;gilead:Honoraria, Other: travel funds;janssen cilag:Honoraria, Other: advisory board, travel funds;roche:Other: travle funds;abbvie:Honoraria, Other: advisory board, travel funds.Ysebaert:AbbVie:Consultancy;Janssen:Consultancy;Roche:Consultancy.Fornecker:Roche:Consultancy;Takeda:Consultancy.Broséus:Gilead:Honoraria;AstraZeneca:Consultancy, Honoraria;Janssen:Honoraria, Research Funding;Novartis:Honoraria, Research Funding.Feugier:astrazeneca:Consultancy, Honoraria, Research Funding;abbvie:Consultancy, Honoraria, Research Funding;roche:Consultancy, Honoraria, Research Funding;gilead:Consultancy, Honoraria, Research Funding;janssen:Consultancy, Honoraria, Research Funding. OffLabel Disclosure: Blinatumomab is a bi-specific T-cell engaging antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells. It has been approved as a second line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.

Ce travail de thèse porte sur la conception et implantation physique d’un micro-réseau sur puce avec garantie de service. Ces études reposent sur le micro-réseau sur puce DSPIN développé au Lip6. Dans un premier temps, nous étudions l’incorporation des communications avec garantie de service dans ce micro-réseau. Ce type de communications est très utilisé dans les systèmes ayant de fortes contraintes temporelles comme, par exemple, les traitements de flux vidéo ou audio. La solution proposée est capable d’offrir des garanties de latence et de bande passante à faible coût matériel. Dans un deuxième temps, nous analysons une FIFO qui permet d’interconnecter des systèmes synchrones qui n’ont pas le même domaine d’horloge. Ce type de FIFO est optimisé pour des profondeurs faibles ainsi que pour faciliter son implantation dans des architectures compatibles avec l’approche Globalement Asynchrone, Localement Synchrone. Sa conception repose sur des cellules standard sans utiliser des cellules spécifiques ni asynchrones. Enfin, nous présentons une implantation matérielle du micro-réseau DSPIN dans la plate-forme FAUST développée par le CEA-Léti. Toute la chaîne de conception, depuis la synthèse de l’architecture jusqu’au dessin des masques, est décrite en détail pour illustrer la façon dont la technologie DSPIN s’intègre dans un flot de conception industriel. Ainsi, le circuit final est testé avec des données réelles.